News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Intrinsic Bioprobes Inc. Announces the Discovery and Exclusive Licensing of Novel Biomarkers for Diabetes



1/21/2010 9:33:26 AM

TEMPE, Ariz., Jan. 21 /PRNewswire/ -- Intrinsic Bioprobes today announced the exclusive licensing of two novel biomarkers for diabetes to Ortho-Clinical Diagnostics, Inc. (Raritan, NJ). The biomarkers are modified forms of blood-circulating proteins and have been linked with the presence of pre-diabetes and type 2 diabetes. The financial terms of the licensing agreement were not disclosed.

The initial discovery of the biomarkers was supported in part by a 5-year, $2M grant from the National Institutes of Health to Intrinsic Bioprobes, in collaboration with researchers from Yale University. "Diabetes is a complex disease, and novel markers could help us understand it better and identify disease subtypes," says Dr. Salvatore Sechi, program director at the National Institute of Diabetes and Digestive and Kidney Diseases. "We are pleased that the scientific discoveries made through the Small Business Technology Transfer Program are of interest to a large diagnostic company."

Intrinsic Bioprobes, Inc. is a privately held Biotechnology Company focused on the development and application of clinical and diagnostic assays and platforms for rapid and sensitive protein biomarker analysis. The company's proprietary technologies consist of Mass Spectrometric Immunoassay (MSIA), a high-performance approach for the selective isolation of proteins from complex biological matrices, and Bioreactive Mass Spectrometer Probes (BRP), devices for rapid, sensitive and accurate protein characterization. These root technologies are incorporated into the MASSAY System, a high-throughput mass spectrometry platform for rapid protein biomarker analysis. For more information about Intrinsic Bioprobes, Inc., please visit http://www.intrinsicbio.com.

Intrinsic Bioprobes, Inc.


Read at BioSpace.com

Related News

comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES